SYNGENE SYNTACS Trademark

Trademark Overview


On Wednesday, July 19, 2023, a trademark application was filed for SYNGENE SYNTACS with the United States Patent and Trademark Office. The USPTO has given the SYNGENE SYNTACS trademark a serial number of 98092301. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Tuesday, June 16, 2026. This trademark is owned by SYNGENE INTERNATIONAL LIMITED. The SYNGENE SYNTACS trademark is filed in the Advertising, Business and Retail Services, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:

Scientific research and custom synthesis in the nature of chemical engineering; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing of materials; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; chemical analysis; drug discovery services; pharmaceutical drug development services; pharmaceutical product development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of companion animals, commercial livestock and wild animals; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; de...

Treatment of materials by polymerization; custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, medicines, drugs by pharmaceutical compounders; contract manufacturing in the field of pharmaceuticals and drug development

Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis a...
syngene syntacs

General Information


Serial Number98092301
Word MarkSYNGENE SYNTACS
Filing DateWednesday, July 19, 2023
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateTuesday, June 16, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 3, 2024

Trademark Statements


Goods and ServicesScientific research and custom synthesis in the nature of chemical engineering; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing of materials; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; chemical analysis; drug discovery services; pharmaceutical drug development services; pharmaceutical product development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of companion animals, commercial livestock and wild animals; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; scientific research in the nature of conducting clinical trials for others in the field of chemical engineering; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific research services relating to the isolation and cultivation of human tissues and cells; preparation of reports relating to scientific and technical research; biochemical analysis in the field of molecular biology; contract scientific research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific laboratory services; services of a chemical or biological scientific laboratory; laboratory research services relating to pharmaceuticals; scientific research and development and scientific research consultation in the fields of antibodies, antibody technology, chemistry, bioinformatics, biomedical, biologics, biotechnology, bio therapeutics, biology, biochemical, cell line, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymer, peptide synthesis, protein, solid state characterization; toxicokinetic, scientific and technological services, namely, scientific research, development, design, testing, and engineering in the fields of antibody, API, biomolecules, cell bank characterization, chiral, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nano particle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications and none of the aforesaid services in the field of agriculture, horticulture and forestry
Goods and ServicesTreatment of materials by polymerization; custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, medicines, drugs by pharmaceutical compounders; contract manufacturing in the field of pharmaceuticals and drug development
Goods and ServicesBusiness services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, August 17, 2023
Primary Code035
First Use Anywhere DateThursday, March 31, 2022
First Use In Commerce DateThursday, March 31, 2022

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, August 17, 2023
Primary Code040
First Use Anywhere DateThursday, March 31, 2022
First Use In Commerce DateThursday, March 31, 2022

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 17, 2023
Primary Code042
First Use Anywhere DateThursday, March 31, 2022
First Use In Commerce DateThursday, March 31, 2022

Trademark Owner History


Party NameSYNGENE INTERNATIONAL LIMITED
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBangalore 560099
IN

Party NameSYNGENE INTERNATIONAL LIMITED
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBangalore 560099
IN

Trademark Events


Event DateEvent Description
Saturday, July 22, 2023NEW APPLICATION ENTERED
Thursday, August 17, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 25, 2024ASSIGNED TO EXAMINER
Wednesday, March 27, 2024NON-FINAL ACTION WRITTEN
Wednesday, March 27, 2024NON-FINAL ACTION E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 27, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 5, 2024NON-FINAL ACTION WRITTEN
Monday, August 5, 2024NON-FINAL ACTION E-MAILED
Monday, August 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 5, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 6, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 27, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 3, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 3, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, December 16, 2024EXTENSION OF TIME TO OPPOSE RECEIVED
Wednesday, May 28, 2025OPPOSITION INSTITUTED NO. 999999
Sunday, June 1, 2025EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Thursday, July 31, 2025OPPOSITION DISMISSED NO. 999999
Thursday, July 31, 2025OPPOSITION TERMINATED NO. 999999
Thursday, July 31, 2025TTAB RELEASE CASE TO TRADEMARKS
Tuesday, September 9, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 9, 2026TEAS STATEMENT OF USE RECEIVED
Monday, March 9, 2026USE AMENDMENT FILED
Tuesday, June 16, 2026STATEMENT OF USE PROCESSING COMPLETE